These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 31926465

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Solriamfetol Titration and AdministRaTion (START) in Patients with Obstructive Sleep Apnea: A Retrospective Chart Review and Hypothetical Patient Scenario.
    Singh H, Hyman D, Parks GS, Chen A, Foley C, Baldys B, Ito D, Thorpy MJ.
    Adv Ther; 2022 Sep; 39(9):4359-4373. PubMed ID: 35927541
    [Abstract] [Full Text] [Related]

  • 43. Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea.
    Abad VC, Guilleminault C.
    Expert Rev Respir Med; 2018 Dec; 12(12):1007-1019. PubMed ID: 30365900
    [Abstract] [Full Text] [Related]

  • 44. A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy.
    Weaver TE, Cuellar N.
    Sleep; 2006 Sep; 29(9):1189-94. PubMed ID: 17040006
    [Abstract] [Full Text] [Related]

  • 45. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
    Krief S, Berrebi-Bertrand I, Nagmar I, Giret M, Belliard S, Perrin D, Uguen M, Robert P, Lecomte JM, Schwartz JC, Finance O, Ligneau X.
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00855. PubMed ID: 34423920
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Test-retest reliability of the Epworth Sleepiness Scale in clinical trial settings.
    Rosenberg R, Babson K, Menno D, Morris S, Baladi M, Hyman D, Black J.
    J Sleep Res; 2022 Apr; 31(2):e13476. PubMed ID: 34545626
    [Abstract] [Full Text] [Related]

  • 48. Oral Appliance Therapy in Patients With Daytime Sleepiness and Snoring or Mild to Moderate Sleep Apnea: A Randomized Clinical Trial.
    Marklund M, Carlberg B, Forsgren L, Olsson T, Stenlund H, Franklin KA.
    JAMA Intern Med; 2015 Aug; 175(8):1278-85. PubMed ID: 26030264
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Pitolisant versus placebo for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: A meta-analysis from randomized controlled trials.
    Wang J, Li X, Yang S, Wang T, Xu Z, Xu J, Gao H, Chen G.
    Pharmacol Res; 2021 May; 167():105522. PubMed ID: 33667687
    [Abstract] [Full Text] [Related]

  • 51. Sodium oxybate improves excessive daytime sleepiness in narcolepsy.
    Black J, Houghton WC.
    Sleep; 2006 Jul; 29(7):939-46. PubMed ID: 16895262
    [Abstract] [Full Text] [Related]

  • 52. Assessing the impact of sodium oxybate treatment on functioning, productivity, and health-related quality of life in patients with narcolepsy: findings from the Nexus Narcolepsy Registry (waves 1-4).
    Thorpy MJ, Ohayon MM, Carls G, Black J, Pasta DJ, Hyman DL, Villa KF.
    Sleep Med; 2021 Aug; 84():380-388. PubMed ID: 34247126
    [Abstract] [Full Text] [Related]

  • 53. Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy.
    Becker PM, Schwartz JR, Feldman NT, Hughes RJ.
    Psychopharmacology (Berl); 2004 Jan; 171(2):133-9. PubMed ID: 14647965
    [Abstract] [Full Text] [Related]

  • 54. Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials.
    Meskill GJ, Davis CW, Zarycranski D, Doliba M, Schwartz JC, Dayno JM.
    CNS Drugs; 2022 Jan; 36(1):61-69. PubMed ID: 34935103
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Update on Persistent Excessive Daytime Sleepiness in OSA.
    Javaheri S, Javaheri S.
    Chest; 2020 Aug; 158(2):776-786. PubMed ID: 32147246
    [Abstract] [Full Text] [Related]

  • 57. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.
    Plazzi G, Ruoff C, Lecendreux M, Dauvilliers Y, Rosen CL, Black J, Parvataneni R, Guinta D, Wang YG, Mignot E.
    Lancet Child Adolesc Health; 2018 Jul; 2(7):483-494. PubMed ID: 30169321
    [Abstract] [Full Text] [Related]

  • 58. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.
    Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, Sonka K, Lehert P, Lecomte I, Lecomte JM, Schwartz JC, HARMONY-CTP study group.
    Lancet Neurol; 2017 Mar; 16(3):200-207. PubMed ID: 28129985
    [Abstract] [Full Text] [Related]

  • 59. Solriamfetol: First Global Approval.
    Markham A.
    Drugs; 2019 May; 79(7):785-790. PubMed ID: 31062265
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.